Vertex Pharmaceuticals Inc
F:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
F:VX1
Watchlist
Price: 404.85 EUR -2% Market Closed
Market Cap: 104.6B EUR
Section:
 

Relative Value

The Relative Value of one VX1 stock under the Base Case scenario is 297.06 EUR. Compared to the current market price of 404.85 EUR, Vertex Pharmaceuticals Inc is Overvalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VX1 Relative Value
Base Case
297.06 EUR
Overvaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10
P/S
P/S
Price to Sales
10
vs History
30
vs Industry
40
Median 3Y
10.2
Median 5Y
9.4
Industry
8.2
Forward
9.6
More Details
32
P/E
P/E
Price to Earnings
32
vs History
1
vs Industry
6
Median 3Y
25.8
Median 5Y
24.9
Industry
24.2
Forward
24.8
More Details
31.7
P/OCF
P/OCF
Price to OCF
31.7
vs History
0
vs Industry
6
Median 3Y
20.7
Median 5Y
20.7
Industry
23
More Details
35.2
P/FCFE
P/FCFE
Price to FCFE
35.2
vs History
0
vs Industry
5
Median 3Y
22.3
Median 5Y
22.3
Industry
25.5
More Details
6.8
P/B
P/B
Price to Book Value
6.8
vs History
23
vs Industry
12
Median 3Y
6.3
Median 5Y
6.2
Industry
3.3
More Details
9.5
EV/S
EV/S
Enterprise Value to Sales
9.5
vs History
28
vs Industry
34
Median 3Y
9.3
Median 5Y
8.4
Industry
8.6
Forward
9.1
More Details
11
EV/GP
EV/GP
Enterprise Value to Gross Profit
11
vs History
26
vs Industry
33
Median 3Y
10.8
Median 5Y
9.5
Industry
10.5
More Details
23.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.5
vs History
20
vs Industry
6
Median 3Y
21.5
Median 5Y
19.3
Industry
6.1
Forward
20.3
More Details
24.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
24.6
vs History
20
vs Industry
5
Median 3Y
22.4
Median 5Y
20.3
Industry
6.6
Forward
20.9
More Details
30
EV/OCF
EV/OCF
Enterprise Value to OCF
30
vs History
0
vs Industry
5
Median 3Y
18
Median 5Y
18
Industry
8.8
More Details
33.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
33.4
vs History
0
vs Industry
5
Median 3Y
19.1
Median 5Y
19.1
Industry
6.8
More Details
7.7
EV/IC
EV/IC
Enterprise Value to IC
7.7
vs History
66
vs Industry
19
Median 3Y
8.1
Median 5Y
8.6
Industry
5.7
More Details

Multiples Across Competitors

VX1 Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
F:VX1
117.7B EUR 10 32 23.5 24.6
IL
Can Fite Biopharma Ltd
TASE:CANF
159.8T ILS 58 252 055.6 -4 000 376.4 -3 925 593.8 -3 916 855.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 004 331.7 -161 617.5 -196 255.2 -194 015.7
US
Abbvie Inc
NYSE:ABBV
389.4B USD 6.5 165.8 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
173.9B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.5B USD 5.2 18.6 12.5 12.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.8 -528.7 -575.7 -560.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.6B USD 5.9 18.5 17.7 20
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.7 19 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.1B USD 15 1 104 148.8 180.4
NL
argenx SE
XBRU:ARGX
41B EUR 13.3 31.3 53.4 54.9
P/S Multiple
Revenue Growth P/S to Growth
US
Vertex Pharmaceuticals Inc
F:VX1
Average P/S: 8 387 138.5
10
10%
1
IL
C
Can Fite Biopharma Ltd
TASE:CANF
58 252 055.6
140%
416 086.1
FR
Pharnext SCA
OTC:PNEXF
34 004 331.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
E
Epizyme Inc
F:EPE
2 071.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15
46%
0.3
NL
argenx SE
XBRU:ARGX
13.3
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Vertex Pharmaceuticals Inc
F:VX1
Average P/E: 176.7
32
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 000 376.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 617.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
10%
1.8
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 104
N/A N/A
NL
argenx SE
XBRU:ARGX
31.3
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vertex Pharmaceuticals Inc
F:VX1
Average EV/EBITDA: 37.8
23.5
16%
1.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 925 593.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
11%
1.6
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
148.8
N/A N/A
NL
argenx SE
XBRU:ARGX
53.4
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vertex Pharmaceuticals Inc
F:VX1
Average EV/EBIT: 43.6
24.6
16%
1.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 916 855.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 015.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20
13%
1.5
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
180.4
N/A N/A
NL
argenx SE
XBRU:ARGX
54.9
N/A N/A

See Also

Summary
VX1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
VX1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VX1 stock valuation using valuation multiples.
Wall Street Estimates
VX1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VX1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.